EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Transforming treatment paradigms: Focus on personalized medicine for high‐grade serous ovarian cancer

Pawel Kordowitzki iD, Britta Lange, Kevin M Elias iD, Marcia C Haigis iD, Sylvia Mechsner iD, Ioana Elena Braicu iD, Jalid Sehouli iD

CA: A Cancer Journal for Clinicians · 2025-10 · 75 (5) · 436-460

DOI: 10.3322/caac.70008 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CA: A Cancer Journal for Clinicians, online erschienen am 19.04.2025. Verfasst von Pawel Kordowitzki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preclinical and Basic Sciences, Nicolaus Copernicus University, Torun, Poland. Hauptthemen laut MEDLINE: Precision Medicine, Ovarian Neoplasms, Cystadenocarcinoma, Serous. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Nicolaus Copernicus University "Excellence Initiative-Research University" IDUB Program Mobility.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High‐grade serous ovarian cancer (HGSOC) is the most common and aggressive subtype of ovarian cancer, accounting for approximately 70% of all ovarian cancer cases and contributing significantly to the high mortality rates associated with this disease. Because of the asymptomatic nature of early stage disease, most patients are diagnosed at advanced stages when the cancer has already spread into the abdominal cavity, requiring complex and intensive surgical and chemotherapeutic interventions followed by maintenance therapies. Although a minority of cases are associated with well defined genetic syndromes, specific risk factors and a clear etiology in many cases remain elusive. HGSOC tumors are characterized by a high frequency of somatic gene copy number alterations, often associated with defects in homologous recombination repair of DNA. All attempts to introduce an effective screening for HGSOC to date have been unsuccessful. This review elucidates the complexities surrounding HGSOC and encompasses its etiology, epidemiology, classification, pathogenesis, and the current array of treatment strategies. Understanding molecular underpinnings is crucial for the development of targeted therapies and personalized multimodal treatment approaches in centralized therapeutic structures. This review also examines the importance of the tumor microenvironment. In addition, the authors' objective is to underscore the critical importance of placing the patient's perspective and diversity at the forefront of therapeutic strategies, thereby fostering a genuinely participatory decision‐making process and ultimately improving patient quality of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineOvarian NeoplasmsCystadenocarcinoma, SerousHumansFemaleNeoplasm GradingTumor Microenvironment

Stichwörter der Autor:innen

diversityhigh‐grade serous ovarian cancerpersonalized medicinequality of lifetreatmenttumor microenvironment

Autor:innen und Institutionen

  • Department of Preclinical and Basic Sciences, Nicolaus Copernicus University, Torun, Poland.
  • Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Gynecology, Center of Oncological Surgery, European Competence Center for Ovarian Cancer, Charité-University Medicine Berlin, Berlin, Germany.
  • Institute for Cultural Studies, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Section of Gynecologic Oncology, Obstetrics and Gynecology Institute, Taussig Cancer Institute, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

ORCID-Profile: Pawel Kordowitzki, Kevin M Elias, Marcia C Haigis, Sylvia Mechsner, Ioana Elena Braicu, Jalid Sehouli

Förderung

  • Nicolaus Copernicus University "Excellence Initiative-Research University" IDUB Program Mobility

Zitieren

APA

Kordowitzki, P., Lange, B., Elias, K. M., Haigis, M. C., Mechsner, S., Braicu, I. E., & Sehouli, J. (2025). Transforming treatment paradigms: Focus on personalized medicine for high‐grade serous ovarian cancer. CA: A Cancer Journal for Clinicians, 75(5), 436-460. https://doi.org/10.3322/caac.70008

Vancouver

Kordowitzki P, Lange B, Elias KM, Haigis MC, Mechsner S, Braicu IE, et al. Transforming treatment paradigms: Focus on personalized medicine for high‐grade serous ovarian cancer. CA: A Cancer Journal for Clinicians. 2025;75(5):436-460. doi:10.3322/caac.70008

BibTeX
@article{Kordowitzki2025,
  author = {Kordowitzki, Pawel and Lange, Britta and Elias, Kevin M and Haigis, Marcia C and Mechsner, Sylvia and Braicu, Ioana Elena and Sehouli, Jalid},
  title = {Transforming treatment paradigms: Focus on personalized medicine for high‐grade serous ovarian cancer},
  journal = {CA: A Cancer Journal for Clinicians},
  year = {2025},
  volume = {75},
  number = {5},
  pages = {436--460},
  doi = {10.3322/caac.70008}
}
Kostenlos starten →